Drug Type Small molecule drug |
Synonyms BAY 59-8862, BAY-59, BAY-59-8862 + [5] |
Target |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC44H57NO17 |
InChIKeyBWKDAMBGCPRVPI-ZQRPHVBESA-N |
CAS Registry186348-23-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Glioblastoma | Phase 2 | IT | - | 01 Nov 2013 |
Metastatic breast cancer | Phase 2 | DE | 01 Apr 2002 | |
Metastatic breast cancer | Phase 2 | GR | 01 Apr 2002 | |
Metastatic breast cancer | Phase 2 | IL | 01 Apr 2002 | |
Metastatic breast cancer | Phase 2 | IT | 01 Apr 2002 | |
Metastatic breast cancer | Phase 2 | PL | 01 Apr 2002 | |
Metastatic breast cancer | Phase 2 | CH | 01 Apr 2002 | |
Metastatic breast cancer | Phase 2 | GB | 01 Apr 2002 | |
Non-Hodgkin's lymphoma refractory | Phase 2 | US | 01 Jan 2002 | |
Non-Hodgkin's lymphoma refractory | Phase 2 | CA | 01 Jan 2002 |
Phase 2 | Recurrent Glioblastoma Second line | 40 | pucwdmzxfv(irmbapvewq) = fhwvknmwag zkodtkoajo (rdbzydfawl ) | Negative | 01 May 2019 | ||
Phase 2 | 40 | mdvccssxvp(icoejspfcs) = ajawlheyhl lbtbaksurt (mzlqdgdsse, 21.8 - 53.8) View more | Positive | 19 Sep 2018 | |||
Phase 2 | 85 | hnibvktbmt(delpandhof) = 2 deaths from liver failure zjegdqdopw (dqxzjqxzng ) | - | 20 May 2008 |